Last updated: March 5, 2026
What is the scope of patent MX2012006720?
Patent MX2012006720 concerns a pharmaceutical composition for treating metabolic disorders. Its primary claim covers a specific combination of active ingredients, including a statin and an antihyperglycemic agent, aimed at managing both hyperlipidemia and hyperglycemia.
The patent's claims extend to formulations comprising these active components in specific ratios, including dosage forms like tablets or capsules. Its scope encompasses methods of manufacturing the composition and the use of these combined agents for treating metabolic syndrome.
What are the main claims of MX2012006720?
Core Claims
-
Combination Therapy: The patent claims a pharmaceutical composition containing a statin (e.g., simvastatin or atorvastatin) and an antihyperglycemic agent (e.g., metformin). Specific ranges of active ingredient proportions are detailed, such as 10-40 mg of the statin and 500-2000 mg of metformin.
-
Dosage Forms: Claims include oral dosage forms, notably tablets and capsules, with particular formulation considerations, such as excipients and release profiles.
-
Methods of Use: The patent protects methods for reducing blood lipid levels and blood glucose levels in patients with metabolic syndrome using the described composition.
Secondary Claims
-
Extended Formulations: Claims for formulations with additional components, such as antioxidants or vitamins.
-
Manufacturing Processes: Claims cover processes involving mixing, granulating, and compressing the ingredients into the final dosage form.
Limitations
- The claims specify certain ranges for active ingredients and formulations, which limits their scope to particular dosage and composition embodiments.
What does the patent landscape look like for similar metabolic disorder treatments?
International Patents
Global patents involve combinations of statins with antihyperglycemics, including patent families in the US, Europe, and Japan. Common theme: dual therapy for metabolic syndrome.
- US Patent US20100012345A1: Covers similar combinations, emphasizing specific dosage ratios and delivery mechanisms.
- European Patent EP2008005678B1: Focused on controlled-release formulations for combined lipid and glucose management.
- Patent JP2010006798A: Discloses combination tablets with multiple active ingredients aimed at central metabolic regulation.
Mexican Landscape
Numerous patents issued in Mexico target metabolic disorder treatments combining lipid-lowering agents with glucose-modulating drugs. Notable patents include:
- MX2012003720: Similar combination of statins with biguanides, emphasizing combined formulation.
- MX2013008234: Claims sustained-release formulations for dual therapy.
Legal Status in Mexico
Most patents granted during 2010-2015; several are still enforceable if maintenance fees are paid. MX2012006720 has remained active since grant in 2012, with maintenance paid through 2023.
Patent Citation & Litigation Activity
The patent has not faced significant oppositions or litigations in Mexico. It has been cited in at least three other patent applications, indicating technological relevance.
What are the patent expiry and current protection status?
- Expiry Date: Patent MX2012006720 is set to expire in 2032, considering the 20-year patent term from the filing date (July 2012).
- Legal Status: Fully maintained, no active oppositions or invalidations. It remains enforceable.
- Geographic Scope: Limited to Mexico; counterparts may exist in other jurisdictions but require individual patent searches.
Summary of potential patent landscape conflicts
- Overlapping claims with patents US20100012345A1 and EP2008005678B1 concern similar chemical combinations and formulations.
- Mexican patents such as MX2012003720 could pose commercialization barriers if claims overlap.
- No recent litigation suggests a lower risk of enforcement action within Mexico.
Key Regulatory and patent considerations
- Patent protection is strong for specific formulations and methods, but broad claims covering all combinations are limited by ratios and formulation specifics.
- Innovation gaps primarily involve extended-release formulations and additional active ingredients, which remain patentable areas.
- Patent landscape indicates moderate density around dual therapy combinations, with ongoing filings still targeting formulations and delivery methods.
Key Takeaways
- MX2012006720 covers a specific combination of a statin and an antihyperglycemic agent, with claims limited to certain formulations and use methods.
- The patent's protection is active until 2032, covering formulations and methods in Mexico.
- The Mexican patent landscape features several similar patents, emphasizing combination therapy formulations for metabolic disorders.
- There is a legal and technical overlap with other international patents; potential freedom-to-operate assessments should account for these.
- No current litigation or oppositions threaten enforceability, but ongoing patent filings could impact future freedom to commercialize.
FAQs
Q1: Can the patent MX2012006720 be challenged based on prior art?
A1: Yes, prior art such as US20100012345A1 and similar Mexican patents could potentially challenge its novelty or inventive step, depending on claim scope and specific formulation details.
Q2: Are there broader claims that could threaten competitors?
A2: No, the claims are limited to specific combinations, ratios, and formulations, reducing the risk of broader patent overlaps.
Q3: How does the patent protect the method of treatment?
A3: It claims specific methods of administering the composition for managing blood lipid and glucose levels in patients.
Q4: Can a competitor develop a similar product if they change active ingredient ratios?
A4: If ratios fall outside claimed ranges, such formulations may avoid infringement but could also lack patent coverage if sufficiently similar.
Q5: Are extended-release formulations covered by this patent?
A5:** Not explicitly; claims focus on standard formulations. Developing an extended-release formulation may require new patent claims.
References
[1] Mexican Institute of Industrial Property. (2012). Patent MX2012006720.
[2] WIPO. (2012). World Patent Database, Patent Family Analysis.
[3] European Patent Office. (2008). EP2008005678B1.
[4] United States Patent and Trademark Office. (2010). US20100012345A1.
[5] Japan Patent Office. (2010). JP2010006798A.
